DUBLIN and AHMEDABAD, India, March 26, 2024 /PRNewswire/ -- Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology.

都柏林和艾哈迈达巴德，印度，2024年3月26日/PRNewswire/--Veeda Clinical Research Limited是一家提供全方位服务的合同研究组织（CRO），拥有公认的药物开发成功记录，宣布收购了Heads，这是一家私人持有的欧洲CRO，专门从事肿瘤学临床试验。

Established in 2010, Heads has an operational presence in 25 multiple strategically important locations across Europe, North America and the Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch..

Heads成立于2010年，在欧洲、北美和亚太地区的25个具有重要战略意义的地点开展业务。通过此次收购，Veeda进入了全球CRO联盟，具备综合能力，将合同研究服务从发现扩展到临床开发，再扩展到商业发布后。

Sharing details related to common synergies between Veeda and Heads, Dr. Mahesh Bhalgat, Group – CEO of Veeda Clinical Research, said, 'With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently.

Veeda Clinical Research首席执行官马赫什·巴尔加特（Mahesh Bhalgat）博士分享了Veeda与Heads之间共同协同作用的细节，他说：“随着对全球临床试验的日益重视，这次收购现在使Veeda能够为多样化的人群提供有效的机会，以便有效地进行大规模的多地理试验。

Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies.'.

这两个组织都致力于推动公平的试验机会，并促进全球创新治疗的发展。此次收购汇集了一支独特的科学家和研究人员团队，他们在肿瘤学研究方面拥有深厚的治疗领域专业知识。这使Veeda能够在不同地区建立长期持久的站点关系。”

Elaborating on the prospects of this partnership, Mr. Binoy Gardi, Executive Vice Chairperson of Veeda Clinical Research, said, 'As we integrate the operations of both the companies, this is an exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients.

Veeda Clinical Research执行副主席比尼·加迪（Binoy Gardi）在阐述这一合作关系的前景时说，“随着我们整合两家公司的运营，这对Veeda和负责人来说是一个令人兴奋的机会，可以拓展市场，利用互补能力，为我们的客户增加价值。

We believe that our combined strengths will enable us to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide.'.

我们相信，我们的综合优势将使我们能够提高效率，创新和卓越，为全球客户的药物开发项目提供研究成果。”

'There is a very strong cultural fit between Heads and Veeda,' said Dr. George Kouvatseas, Partner, Heads. 'Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, and an uncompromising focus on quality. During the integration phase, Heads will continue to offer uninterrupted support to client programs.

“海德斯和维达之间有着非常强烈的文化契合，”海德斯合伙人乔治·库瓦特西博士说两家公司都致力于科学领导，扩展高度专业化的服务以满足客户的新兴需求，并毫不妥协地关注质量。在集成阶段，负责人将继续为客户计划提供不间断的支持。

The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programs.'.

Veeda和Heads共同致力于通过结构化集成流程实现灵活的运营，而不影响正在进行的客户计划。”

About Veeda Clinical Research Limited:

关于Veeda Clinical Research Limited：

Veeda Clinical Research Limited ('Veeda') is one of the largest independent, full-service clinical research organizations, headquartered in Ahmedabad, India. Veeda offers a range of bioequivalence studies and early and late phase clinical trials. Veeda has successfully completed several regulatory inspections and is approved by USFDA, UK MHRA, ANVISA (Brazil), and WHO.

Veeda Clinical Research Limited（“Veeda”）是最大的独立、全方位临床研究组织之一，总部位于印度艾哈迈达巴德。Veeda提供了一系列生物等效性研究以及早期和晚期临床试验。Veeda已成功完成多项监管检查，并获得USFDA、英国MHRA、ANVISA（巴西）和WHO的批准。

Veeda has experience in conducting complex clinical studies. Visit https://www.veedacr.com/..

Veeda拥有进行复杂临床研究的经验。访问https://www.veedacr.com/..

About Heads:

关于头部：

Heads is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in haemato-oncology studies. It provides complete range of clinical trial services, from start-up to completion, from Phase I to IV. In addition, it offers strategic oncology drug development consulting and expert advice, as the team understands the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market.

Heads是一家全方位服务的全球合同研究组织（CRO），致力于进行临床研究，拥有血液肿瘤学研究的专业知识。它提供从启动到完成，从第一阶段到第四阶段的全套临床试验服务。此外，它还提供战略性肿瘤药物开发咨询和专家建议，因为团队了解在复杂，竞争激烈且快速发展的肿瘤市场中开发抗癌药物的挑战。